Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Carisbamate - SK biopharmaceuticals

Drug Profile

Carisbamate - SK biopharmaceuticals

Alternative Names: Comfyde; JNJ-10234094; RWJ-333369; YKP-509

Latest Information Update: 23 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator SK biopharmaceuticals
  • Developer Janssen Research & Development; Johnson & Johnson Pharmaceutical Research & Development; Johnson & Johnson Pharmaceutical Research & Development LLC; Ortho-McNeil Pharmaceutical; SK biopharmaceuticals
  • Class Antiepileptic drugs; Carbamates; Chlorinated hydrocarbons; Neuroprotectants; Non-opioid analgesics; Small molecules
  • Mechanism of Action Neurotransmitter modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Infantile spasms
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Lennox-Gastaut syndrome
  • Discontinued Diabetic neuropathies; Epilepsy; Essential tremor; Migraine; Postherpetic neuralgia

Most Recent Events

  • 22 May 2019 Phase-II clinical trials in Lennox-Gastaut syndrome in USA (PO) (SK Biopharmaceuticals pipeline, May 2019)
  • 03 May 2019 SK Life Science initiates a phase I extension trial for Lennox gastaut syndrome (In adult, In children) in USA (NCT04062981)
  • 15 Nov 2018 Discontinued - Phase-I for Epilepsy (PO) (SK Life Science pipeline, November 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top